
The U.S. Supreme Court on Wednesday refused to lift a lower‑court injunction that bars the Federal Bureau of Prisons (BOP) from enforcing a February 2026 policy restricting transgender inmates’ access to hormone therapy and other gender‑affirming accommodations.
Three transgender prisoners had sued, arguing the rule violated their rights. In August, Senior U.S. District Judge Royce Lamberth ordered the BOP to halt the policy, and a D.C. Circuit panel later denied the government’s request to freeze that order. The administration asked the Supreme Court to pause the injunction, but the Court issued a brief, unsigned order rejecting the request.
The February 2026 rule would stop transgender inmates from receiving hormone treatments and “social accommodations” such as makeup, wigs, and padding. The BOP said it adopted the policy independently of a 2025 executive order that barred federal funds for procedures intended to change an inmate’s appearance to that of the opposite sex. The agency cited “latest scientific information” and concerns about safety, fairness, and resentment among other prisoners.
The government, represented by Solicitor General D. John Sauer, argued that the district court overstepped by substituting its own policy judgment for the BOP’s, relying on evidence outside the agency’s record, and denying prison officials the deference they deserve. The inmates countered that the administration was trying to overturn a three‑decade‑long status quo and that the BOP had failed to provide a reasoned explanation for the change, risking serious mental‑health harms.
Because the Supreme Court left the lower‑court order in place, the BOP must continue its prior practices, allowing hormone therapy and other gender‑affirming care to continue for the three plaintiffs and any similarly situated inmates. No new deadlines or steps were set by the Court.
While the decision affects only federal prisons, it signals that challenges to agency policies that limit transgender healthcare may succeed if plaintiffs can show lack of reasoned justification. Inmates or advocates who believe a policy harms them should consider filing a lawsuit or seeking a court order to preserve existing care.
Anyone facing a similar situation—whether in prison or another government‑run facility—may benefit from consulting an attorney to assess whether the agency’s actions comply with statutory and constitutional requirements.
Transgender inmates in federal prisons will continue receiving hormone therapy and related care for now.
The case highlights that courts may scrutinize agency policies that lack clear justification, especially on sensitive health issues.
Other federal facilities could face similar lawsuits if they try to limit transgender healthcare without a solid record.
The decision does not create new rights but preserves existing care for the plaintiffs and similarly situated inmates.
Inmates or advocates who believe a policy harms them should consult an attorney about filing a suit or seeking an injunction.
Federal rules apply nationwide, but your options depend on your state and situation. Browse attorneys by practice area, then pick your state.
This article is general information based on SCOTUSblog and court or agency records available at publication time. It is not legal advice; laws and deadlines differ by state and by case. Published October 21, 2026.
Source: SCOTUSblog
The high court denied the Trump administration’s request to halt gender‑affirming treatment for roughly 1,000 transgender inmates, keeping existing medical standards in place.
Analysis of 165 Supreme Court emergency applications shows Trump administrations prevailed in about 78% of their own requests, while Biden succeeded in 67% of similar filings.
The Supreme Court’s Wolford ruling limits courts to a narrow textual inquiry for the first step of the Bruen test, shifting historical analysis to the second step.
The high court granted the FCC’s request to stay a lower-court order, leaving current favorable advertising rates for parties and committees unchanged.
The FDA launched an initiative to reimagine drug development, aiming to speed up safe treatments for rare disease patients in small populations.